Durvalumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Durvalumab
- Durvalumab: From Urothelial Carcinoma to Prostatic Urethra Urothelial Carcinoma and Beyond
Durvalumab: From Urothelial Carcinoma to Prostatic Urethra Urothelial Carcinoma and Beyond
One-Sentence Summary
Durvalumab (IMFINZI) is an anti-PD-L1 monoclonal antibody checkpoint inhibitor approved in multiple markets for urothelial carcinoma and non-small cell lung cancer, though not currently registered in Saudi Arabia. The TxGNN model predicts it may be effective for 10 rare urothelial and gynecological cancer subtypes — the highest TxGNN score goes to Prostatic Urethra Urothelial Carcinoma (99.98%), while Endocervical Carcinoma (Rank #6) carries the strongest clinical evidence with 2 clinical trials and 1 publication. Evidence levels range from L2 to L5 across predicted indications; most require further investigation before clinical translation, with endocervical carcinoma as the one actionable candidate.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Urothelial carcinoma, NSCLC, biliary tract cancer (approved in other markets; original indication data not captured in this Evidence Pack) |
| Predicted New Indication (Top TxGNN Score) | Prostatic Urethra Urothelial Carcinoma |
| TxGNN Prediction Score | 99.98% (Rank #746) |
| Evidence Level (Rank #1 Indication) | L5 — Model prediction only |
| Best-Evidenced Indication | Endocervical Carcinoma (Rank #6, L2) |
| Saudi Arabia Market Status | ✗ Not Marketed (0 authorizations) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold (7 indications) · Research Question (2 indications) · Proceed with Guardrails (Endocervical Carcinoma) |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from this Evidence Pack (Data Gap DG002). Based on known pharmacological information, Durvalumab is a human IgG1 monoclonal antibody that selectively blocks PD-L1 from binding its receptors PD-1 and CD80, thereby restoring T-cell-mediated immune surveillance against tumors. This mechanism — immune checkpoint blockade at the PD-L1 node — has proven effective across multiple solid tumors where PD-L1 upregulation enables immune evasion.
The 10 predicted indications cluster around two biological themes. The first group comprises urothelial/transitional cell carcinoma subtypes (prostatic urethra, kidney pelvis sarcomatoid, bladder sarcomatoid variant, renal pelvis papillary), where PD-L1 expression is documented at 30–60% in conventional urothelial carcinoma and is notably higher (>60% in some studies) in sarcomatoid variants due to epithelial-mesenchymal transition (EMT) activation and elevated tumor mutational burden (TMB). The second group comprises gynecological adenocarcinoma subtypes (endocervical, uterine ligament variants, cervical mucinous variants), where HPV-driven immune evasion — including PD-L1 upregulation — creates a theoretical basis for checkpoint inhibition. Importantly, the related anti-PD-1 agent pembrolizumab is already FDA-approved for cervical cancer, validating the PD-1/PD-L1 axis as a clinically meaningful target in this tumor class.
The mechanistic rationale is strongest for sarcomatoid urothelial variants (EMT, high PD-L1, high TMB) and HPV-positive endocervical carcinoma (PD-L1 upregulation in ~30–60% of cases). It is weakest for adenoid cystic carcinoma of the cervix (typically immunologically cold, TMB-low) and signet ring cell/intestinal mucinous cervical variants (immunosuppressive tumor microenvironment unless MSI-H).
All Predicted Indications — Summary
| Rank | Disease | TxGNN Score | Evidence Level | Decision |
|---|---|---|---|---|
| 1 | Prostatic Urethra Urothelial Carcinoma | 99.98% | L5 | Hold |
| 2 | Kidney Pelvis Sarcomatoid TCC | 99.98% | L4 | Research Question |
| 3 | Infiltrating Bladder UC Sarcomatoid Variant | 99.98% | L3 | Research Question |
| 4 | Renal Pelvis Papillary UC | 99.98% | L5 | Hold |
| 5 | Uterine Ligament Adenocarcinoma | 99.92% | L5 | Hold |
| 6 | Endocervical Carcinoma | 99.91% | L2 | Proceed with Guardrails |
| 7 | Adenoid Cystic Carcinoma of Cervix Uteri | 99.91% | L5 | Hold |
| 8 | Uterine Ligament Serous Adenocarcinoma | 99.91% | L5 | Hold |
| 9 | Signet Ring Cell Variant Cervical Mucinous Adenocarcinoma | 99.90% | L5 | Hold |
| 10 | Intestinal Variant Cervical Mucinous Adenocarcinoma | 99.90% | L5 | Hold |
Clinical Trial Evidence
Clinical trial evidence exists for Indications #2, #3, and #6 only. Indications #1, #4, #5, #7, #8, #9, and #10 have no registered clinical trials.
For Indication #3 — Infiltrating Bladder UC Sarcomatoid Variant
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03912818 | Phase 2 | Terminated | 7 | Durvalumab + neoadjuvant chemotherapy in variant histology bladder cancer. Critical signal: terminated after enrolling only 7 patients (far below target). Termination reason must be clarified — if due to insufficient efficacy, this is a significant negative signal; if due to accrual/funding difficulties, the indication may warrant re-evaluation. |
| NCT02812420 | Early Phase 1 | Active, Not Recruiting | 54 | Durvalumab + Tremelimumab (dual checkpoint: anti-PD-L1 + anti-CTLA-4) pre-surgical in muscle-invasive, cisplatin-ineligible high-risk urothelial carcinoma. Covers the broader urothelial population including bladder; dual checkpoint blockade may offer additional synergy for sarcomatoid variants. Indirect relevance only. |
For Indication #2 — Kidney Pelvis Sarcomatoid TCC
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02812420 | Early Phase 1 | Active, Not Recruiting | 54 | Same trial as above — the urothelial carcinoma population may include upper tract (renal pelvis) cases. Not designed for sarcomatoid TCC of the kidney pelvis. Indirect relevance; supports the broader concept of durvalumab in urothelial disease. |
For Indication #6 — Endocervical Carcinoma
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04065269 | Phase 2 | Active, Not Recruiting | 174 | ATARI trial: ceralasertib (ATR inhibitor) alone or combined with olaparib or durvalumab in relapsed gynecological cancers, stratified by ARID1A loss. Largest available dataset (n=174). Key limitation: three-drug combination arms make it difficult to isolate durvalumab's independent contribution; patient selection is biomarker-driven (DDR deficiency). Expected completion August 2026. |
| NCT03452332 | Phase 1 | Completed | 20 | Hypofractionated radiotherapy + durvalumab + tremelimumab in recurrent/metastatic cervical, vaginal, or vulvar cancers. Completed — safety profile of durvalumab in the cervical cancer population has been established. Publication status of results should be confirmed. |
Literature Evidence
Literature was found for Indication #6 (Endocervical Carcinoma) only. Indications #1–5 and #7–10 have no related publications in the Evidence Pack search.
For Indication #6 — Endocervical Carcinoma
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37467967 | 2023 | Review | Biomedical Journal | Molecular basis and therapeutic advances in small cell neuroendocrine carcinoma of the cervix (SCNECC). Discusses HPV association, evidence gaps in rare cervical subtypes, and immunotherapy potential. Indirectly informs PD-L1 pathway rationale for endocervical carcinoma; direct evidence for durvalumab not addressed. |
Saudi Arabia Market Information
Durvalumab has no registered authorizations in Saudi Arabia (0 licenses, not marketed). No authorization records to display.
Cytotoxicity
Durvalumab is an antineoplastic drug (immune checkpoint inhibitor targeting PD-L1 in solid tumors). This section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted immunotherapy — Immune Checkpoint Inhibitor (anti-PD-L1 IgG1 monoclonal antibody); not conventional cytotoxic chemotherapy |
| Myelosuppression Risk | Low — mechanism does not directly suppress bone marrow; immune-mediated cytopenias (e.g., immune thrombocytopenia, hemolytic anemia) are rare but recognized immune-related adverse events (irAEs) |
| Emetogenicity Classification | Minimal — IV biologic; emetogenic risk is negligible compared to conventional chemotherapy |
| Monitoring Items | CBC with differential (baseline and periodic), liver function (ALT/AST — immune hepatitis), thyroid function (TSH/fT4 — thyroiditis), creatinine/BUN (immune nephritis), blood glucose (immune endocrinopathy), pulmonary assessment (chest imaging if pneumonitis symptoms) |
| Handling Protection | Standard biohazard precautions for injectable biologics; specialized cytotoxic handling protocols (closed system, double glove, negative pressure) are not required for monoclonal antibodies under most institutional guidelines — verify against local pharmacy SOPs |
Safety Considerations
Please refer to the package insert for safety information.
(Key warnings, contraindications, and drug interaction data were not available in this Evidence Pack. TFDA package insert retrieval is flagged as a Blocking data gap [DG001] and must be resolved before safety screening can proceed. No drug-drug interactions were identified in the DDI database query.)
Conclusion and Next Steps
Endocervical Carcinoma (Rank #6) — Proceed with Guardrails
Rationale: The PD-1/PD-L1 axis is clinically validated in cervical cancer (pembrolizumab holds FDA approval), HPV-driven PD-L1 upregulation provides a strong mechanistic basis, and durvalumab specifically is under active investigation in gynecological cancer clinical trials (Phase 1 completed, Phase 2 active with n=174), placing this indication at evidence Level L2.
To proceed, the following is needed:
- Confirm endocervical carcinoma representation within NCT04065269 and obtain interim efficacy readouts
- Retrieve published results from completed NCT03452332 (Phase 1 safety data)
- Define biomarker strategy: PD-L1 IHC (CPS ≥1 or ≥10), HPV status, MSI/MMR, TMB
- Initiate Saudi Arabia regulatory pathway: durvalumab requires full NDA/BLA submission or compassionate use framework (0 current authorizations)
- Resolve Blocking data gap DG001: retrieve SFDA/TFDA package insert for safety screening
Urothelial Sarcomatoid Variants — Indications #2 and #3 — Research Question
Rationale: Sarcomatoid variants carry elevated PD-L1 expression and strong immunological rationale, but NCT03912818 (the only Phase 2 trial directly targeting variant histology bladder cancer with durvalumab) was terminated with only 7 patients enrolled — a critical negative signal. The cause of termination is unknown and determines whether this indication warrants further investment.
To proceed, the following is needed:
- Investigate and document termination reason for NCT03912818
- Biomarker characterization of sarcomatoid TCC: PD-L1 expression, TMB, EMT marker profile
- Explore basket trial inclusion or investigator-initiated study design for rare sarcomatoid urothelial subtypes
All Other Indications (#1, #4, #5, #7, #8, #9, #10) — Hold
Rationale: These 7 indications have no clinical trials or literature support. TxGNN scores reflect knowledge-graph topological proximity to adjacent cancer nodes — not clinical validation. Specific mechanistic concerns include: adenoid cystic carcinoma of the cervix is typically immunologically cold (TMB-low, PD-L1 negative, poor historical response to ICIs); signet ring cell and intestinal variants respond poorly to ICI unless MSI-H/dMMR; uterine ligament adenocarcinomas have near-zero PD-L1 characterization data.
Minimum requirements before reconsideration:
- Subtype-specific PD-L1 expression and TMB data
- At least preclinical evidence (cell line or patient-derived xenograft) for direct mechanistic support
- Biomarker-selected patient identification criteria (MSI-H, TMB-H, PD-L1 CPS) before any prospective study design
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.